{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'If either PFS or OS endpoint reaches statistical significance, the study is considered', 'positive. No further tests will be performed if the OS endpoint in DLL3 high population', '(H01b) does not reach statistical significance.', 'The hypothesis in H02 will be tested if the hypothesis in Holb is rejected. If the hypothesis', 'in H02 is rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS', 'endpoint in DLL3 high subjects (Ho1a) is also rejected or (ii) only H04 will be tested if the', 'PFS endpoint in DLL3 high subjects (H01a) is not rejected.', 'Diagram of Hierarchical Testing of Primary and Secondary Endpoints is described in', 'Figure 3.', '103']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Enppoints', 'Test Hola (PFS in DLL: 3High set) at one-sided a = 0.25%', 'If Ho1a not rejected', 'If Holaisrejected', 'Test Holb (OS in DLL3', 'Test Holb (OS in DLL3High', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Holb isrejected', 'If Holb is rejected', 'Test Ho2 (OS in Randomized', 'Test Ho2 (OS in Randomized', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Ho2 is rejected', 'If Ho2 is rejected', 'Test Ho4 (PF scale in EORTC', 'Test Ho3 (PFS in Randomized', 'QLQ-C30 in Randomized set)', 'set) at one-sided a = 2.4999%', 'at one-sided a = 2.2499%', 'If H03 is rejected', 'Test Ho4 (PF scale in EORTC', 'QLQ-C30 in Randomized set)', 'at one-sided a = 2.2499%', '104']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.4', 'Determination of Sample Size', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS) in DLL3high ED SCLC patients. To', 'maintain the overall 1-sided type I error at a 2.5% for this study, the type I error will be', 'split, assigning 0.25% to progression-free survival and the remaining 2.25% to overall', 'survival. However, the OS endpoint will be tested at a one-sided 2.2499% significance', 'level as a one-sided alpha of 10-6 will be spent for the early look at the OS data for futility', 'analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo and rovalpituzumab tesirine arm will be around 9 months and 13', 'months, respectively. The increase of median os in rovalpituzumab tesirine arm', 'corresponds to a hazard ratio of 0.69, i.e., a reduction in the hazard of death by 31%.', 'With all these assumptions, a total of 319 deaths among subjects with DLL3 high are needed', 'to achieve a 90% power based on a log-rank test at a one-sided significance level of', '0.022499. Assuming a 19-month accrual period and the last enrolled subject followed for', '12 months, at least 480 subjects with DLL3 high are expected to be randomized', '(240 subjects in each arm). A total of 740 subjects regardless of DLL3 expression level', '(including 480 subjects with DLL3high) will enroll in the study, assuming an approximate', 'prevalence of 65% for subjects with DLL3high For one-sided significance level of', '0.022499, it is projected that an observed hazard ratio of 0.799 or less, corresponding to a', '2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The primary endpoints of OS and PFS in DLL3 high patients will be analyzed at the same', 'time after observing at-least 319 OS event. It is expected at approximately 420 PFS', 'events will be observed at the time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that', 'median progression-free survival for the placebo and rovalpituzumab tesirine arm will be', '105']\n\n###\n\n", "completion": "END"}